The PRODIGE 7 randomized trial has 4 design flaws and 4 pharmacologic flaws and cannot be used to discredit other HIPEC regimens. 

 -  2021 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>2078-6891 
<br/><br/><label>Standard No.: </label>10.21037/jgo-2020-15 [doi] jgo-12-S1-S129 [pii] PMC8100721 [pmc] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>IN PROCESS -- NOT YET INDEXED
<br/><br/><label>Subjects--Geographic Terms: </label><br/>Washington Cancer Institute
<br/><br/><label>Index Terms--Function: </label><br/>Comment<br/>Editorial